Clinical trials: Active Ankylosing Spondylitis
Ankylosing Spondyloarthritis
Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines.
- Trial name
- POSTURE (NCT01583374)
- Testing
- Apremilast tablet 20 mg, Apremilast tablet 30 mg BID
- Where
- 103 sites in United States, Australia and 16 more
- Volunteers
- 490 people
- Sponsor
- Amgen
Active Ankylosing Spondylitis
Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.
- Trial name
- NCT07172360
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Ankylosing Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
The purpose of this trial is to demonstrate the clinical efficacy at week 16; and to demonstrate safety and tolerability of secukinumab compared to placebo in patients with ankylosing spondylitis at week 16 and long term safety…
- Trial name
- NCT02896127
- Testing
- Secukinumab
- Where
- 44 sites in China, Czechia and 2 more
- Volunteers
- 458 people
- Sponsor
- Novartis Pharmaceuticals
Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and…
- Conditions
- Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
- Trial name
- NCT03357471
- Testing
- e-Device
- Where
- 22 sites in United States
- Volunteers
- 70 people
- Sponsor
- UCB Biopharma S.P.R.L.
Anklyosing Spondylitis
16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
This study assessed the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who were tolerant to or had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor
- Trial name
- MEASURE2 (NCT01649375)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 53 sites in United States, Austria and 11 more
- Volunteers
- 219 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
Effects of Etanercept on the Heart, Veins and Thickness of Certain Major Arteries In Ankylosing Spondylitis Patients
Study to assess whether etanercept therapy is able to increase flow-mediated vasodilatation in AS, and whether etanercept can modify the intima-media thickness (IMT) in these patients
- Trial name
- CREST (NCT00910273)
- Testing
- etanercept
- Where
- 4 sites in Italy
- Volunteers
- 34 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)
The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.
- Trial name
- NCT03502616
- Testing
- Tofacitinib
- Where
- 99 sites in United States, Australia and 12 more
- Volunteers
- 270 people
- Sponsor
- Pfizer
Non-radiographic Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
The purpose of this study was to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and safety up to Week…
- Trial name
- PREVENT (NCT02696031)
- Testing
- Secukinumab
- Where
- 139 sites in United States, Australia and 22 more
- Volunteers
- 555 people
- Sponsor
- Novartis Pharmaceuticals
Spondylitis, Ankylosing
A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED)
The objective of this study is to prove reasonability of registration in Russian federation this new indication (ankylosing spondylitis [AS]) through evaluation of safety and efficacy rate of Remicade 5mg/kg, given as an…
- Trial name
- NCT00779012
- Testing
- Infliximab
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Ankylosing Spondylitis
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)
The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.
- Trial name
- NCT05861128
- Testing
- Jaktinib
- Where
- China
- Volunteers
- 207 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Ankylosing Spondylitis
Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis
Study of the efficacy and safety of adalimumab compared with placebo in adult Chinese participants with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal…
- Trial name
- NCT01114880
- Testing
- adalimumab
- Where
- 9 sites in China
- Volunteers
- 344 people
- Sponsor
- Abbott
Ankylosing Spondylitis
Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis
The goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with Active Ankylosing Spondylitis.
- Trial name
- NCT07277179
- Testing
- Netakimab
- Where
- China
- Volunteers
- 113 people
- Sponsor
- SPH-BIOCAD (HK) Limited
Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Efficacy and Safety Study of SUNPG1622
This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.
- Trial name
- NCT02980705
- Testing
- SUNPG1622 I dose
- Where
- 4 sites in United States, Hungary and 2 more
- Volunteers
- 180 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Ankylosing Spondylitis
Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis
The purpose of this study was to assess the clinical efficacy, safety and tolerability of secukinumab subcutaneous injections up to 52 weeks in Japanese patients with active AS despite current or previous non-steroidal…
- Trial name
- NCT02750592
- Testing
- Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
- Where
- 10 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Active Ankylosing Spondylitis
Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study. The study was divided into three stages, including screening period(4-week), treatment period(16-week) and observation period.
- Trial name
- NCT05407246
- Testing
- Hemay005
- Where
- 11 sites in China
- Volunteers
- 90 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA
EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries
This is a non-interventional, post-marketing, observational study (PMOS) in which Humira (adalimumab) is prescribed in the usual manner in accordance with the terms of the local marketing authorization with regards to dose…
- Conditions
- Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA, Rheumatoid Arthritis (RA
- Trial name
- EviraEAST (NCT01078402)
- Where
- 163 sites in Croatia, Hungary and 5 more
- Volunteers
- 809 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Axial Spondyloarthrithis, Ankylosing Spondylitis
Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo
Patients receive study drug for one year (Part A). If, after the initial run-in phase, a sustained remission is reached they will be randomly split into one of three dose groups for another year (Part B).
- Trial name
- C-OPTIMISE (NCT02505542)
- Testing
- Certolizumab Pegol
- Where
- 108 sites in United States, Belgium and 12 more
- Volunteers
- 736 people
- Sponsor
- UCB BIOSCIENCES GmbH
Ankylosing Spondylitis
Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in patients with active ankylosing spondylitis
- Trial name
- NCT04840485
- Testing
- SHR-1314
- Where
- China
- Volunteers
- 548 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Ankylosing Spondylitis
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
The purpose of this study is to demonstrate the impact of secukinumab on the progression of structural damage in the spine, as measured by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) in patients with Ankylosing…
- Trial name
- SURPASS (NCT03259074)
- Testing
- GP2017 (adalimumab biosimilar), AIN457 150 mg
- Where
- 171 sites in United States, Argentina and 27 more
- Volunteers
- 859 people
- Sponsor
- Novartis Pharmaceuticals
Spondylitis, Ankylosing
Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)
This is a Phase 4, multi-center, open-label, one-arm, pilot study in patients with active ankylosing spondylitis refractory to conventional treatment.
- Trial name
- NCT00779935
- Testing
- Remicade
- Volunteers
- 44 people
- Sponsor
- Merck Sharp & Dohme LLC